Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors

Clinical Cancer Research

Volumn 13, Issue 19, 2007, Pages 5841-5846

  Fornier, M N ^a   Rathkopf, D ^a   Shah, M ^a   Patil, S ^a   O'Reilly, E ^a   Tse, A N ^a   Hudis, C ^a   Lefkowitz, R ^a   Kelsen, D P ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DOCETAXEL; FLAVOPIRIDOL; GEMCITABINE; IRINOTECAN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; LACRIMATION; LUNG EMBOLISM; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CARCINOMA; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SINUS TACHYCARDIA; SOLID TUMOR; THROMBOSIS; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; FLAVONOIDS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PIPERIDINES; TAXOIDS; TREATMENT OUTCOME;

EID: 35348859609     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1218     Document Type: Article

References (17)

1. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266:1821-8.
2. Harper J, Elledge SJ. Cdk inhibitors in development and cancer. Curr Opin Genet Dev 1996;6:56-64.
3. Maik RG, Kattice SL, Bhat SV, Alreja B, DeSouza NJ, Rupp RH. An anti-inflammatory cum immunomodulatory piperidinylbenzopyranone from dysoloxylum binectiferum: isolation, structure and total synthesis. Tetrahedron 1988;44:2081-6.
4. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005;3:9408-21.
5. 1 arrest with inhibition of cyclin-dependent kinase CDK2 and CDK4 in human breast carcinoma cells. Cancer Res 1996;56:2973-8.
6. Losiewicz MD, Carlson BA, Kaur G, et al. Potent inhibition of cdc2 kinase activity by the flavonoid L86-8275. Biochem Biophys Res Commun 1994;201:589-95.
7. Schwartz GK. Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol 2005;23:4499-508.
8. Sambol EB, Ambrosini G, Geha RC, et al. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res 2006;66:5858-66.
9. Wirger A, Perabo FG, Burgemeister S, et al. Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res 2005;25:4341-7.
10. Motwani M, Delohery TM, Schwartz GK. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin Cancer Res 1999;5:1876-83.
11. Motwani M, Rizzo C, Sirotnak F, et al. Flavopiridol enhances the effect of docetaxel in vitro and in vivo in human gastric cancer cells. Mol Cancer Ther 2003;6:549-55.
12. Schwartz GK, O'Reilly E, Ilson D, et al. A phase I study of cyclin dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol 2002;20:2157-70.
13. Shah M, Kortmansky J, Motwani M, et al. A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol. Clin Cancer Res 2005;11:3836-45.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
15. Bible KC, Lensing JL, Nelson SA, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res 2005;11:5935-41.
16. Tan A, Yang X, Berman A, et al. Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res 2004;10:5038-47.
17. El-Rayes BF, Gadgeel S, Parchment R, et al. A phase I study of flavopiridol and docetaxel. Invest New Drugs 2006;24:305-10.